Vaishali Pharma has received approval and Registration for Five new products i.e. VEGAFLU, VIPRIN 75, VIPROAZ –SUSPENSION, MALPHAREX and CELLARGY from the Ministry of Health and Medicine of Turkmenistan. These products have a good demand in the local markets of Turkmenistan. This remarkable achievement in the symbolizes a landmark and enables the Company to strengthen its presence in the high growth market of Turkmenistan and enables the Company to reach out to more and more territories. The Company also plans to register the similar range of products in the neighboring Countries.
Turkmenistan Health care industry has shown one of the strongest growth rates in the Central Asia region with annual spending growth rate of around 18% and CAGR for coming five years is expected to be over 12%. Government has developed strong health care modernization plan.
Vaishali Pharma is a pharmaceutical company, dealing in pharmaceutical formulations, APIs, surgical products, veterinary supplements. It is operating both in domestic and export markets.
| Company Name | CMP |
|---|---|
| Redington | 227.35 |
| Adani Enterprises | 2225.25 |
| Amrapali Industries | 17.27 |
| Rashi Peripheral | 474.40 |
| PDS | 291.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: